Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05581004 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05581004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05581004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 20, 2022
Completion date
July 31, 2028
Enrollment
165 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, clear cell rcc, colorectal cancer, esophageal cancer, gastric cancer, hcc, hnscc, locally advanced or metastatic solid tumors, melanoma, nsclc, tnbc, urothelial carcinoma